Business
Cellectar Announces Poster Presentation of CLR 131 Data in Waldenstrom’s Macroglobulinemia at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
Management to host a KOL call with Dr. Sikandar Ailawadhi, M.D., lead investigator on June 4 at 10:00 am FLORHAM PARK, N.J., May 20, 2021 (GLOBE NEWSWIRE) --
About this update from Cellectar Biosciences, Inc.
[{"type":"text","content":"Management to host a KOL call with Dr. Sikandar Ailawadhi, M.D., lead investigator on June 4 at 10:00 am\nFLORHAM PARK, N.J., May 20, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced a poster presentation at the American Society of Clinical Oncology (ASCO) Annual meeting to be held virtually June 4-8, 2021. The poster presentation on June 4th will provide an in-depth update of the six patients reported in the Abstract from the company’s Phase 2a study of CLR 131 in Waldenstrom’s macroglobulinemia (WM). A copy of the Abstract, entitled: Treatment Free Remission (TFR) and Overall Response Rate (ORR) Results in Patients with Relapsed/Refractory Waldenstrom’s Macroglobulinemia (WM) Treated with CLR 131 is available on ASCO’s website www.asco.org. In conjunction with the poster presentation, management is hosting a KOL call with Dr. Sikander Ailawadhi, M.D., the lead investigator for the company’s Phase 2 CLOVER-1 study of CLR 131 in patients with relapsed/refractory B-cell hematologic cancers. Dr. Ailawadhi is a Professor of Medicine, Lead, International Cancer Center, Division of Hematology/Oncology, Departments of Medicine and Cancer Biology at Mayo Clinic Florida. He was awarded the 2013 NCI CCITLA as an Assistant Professor of Medicine at the Norris Cancer Center, University of Southern California (USC), Los Angeles, CA. Subsequently, he joined the Division of Hematology and Oncology at Mayo Clinic in Florida as a Senior Consultant in order pursue his career goal of clinical, translational and outcomes-based research in B-cell malignancies. Dial-in & Webcast informationDomestic: 877-705-6003International: 201-493-6725Conference ID: 13719983Webcast: http://public.viavid.com/index.php?id=145036 A replay of the call will be available on the Events page of company website following the live event. About the Pivotal Trial of CLR 131 in Waldenstrom’s macroglobulinemia (WM)The pivotal trial is designed as a global, non-comparator, single arm, expansion cohort of the currently ongoing Phase 2 CLOVER-1 study of CLR 131. The study will enroll 50 WM patients. Patients in the trial will receive up to four doses of CLR 131 over two cycles (cycle one days 1, 15, and cycle two days 57...